Lessons from BCG for SARS-CoV-2 vaccine candidates

J Infect Dis. 2020 Nov 30;jiaa637. doi: 10.1093/infdis/jiaa637. Online ahead of print.

Authors

Marcel A Behr^{1

2

3

4}, Maziar Divangahi^{1

2

4

5}, Erwin Schurr^{1

2

3

4}

Affiliations

¹ Department of Medicine, McGill University.
² McGill International TB Centre.
³ Infectious Diseases and Immunity in Global Health, MUHC Research Institute.
⁴ McGill Interdisciplinary Initiative in Infection and Immunity.
⁵ Meakins-Christie Laboratories.

PMID: 33252679
DOI: 10.1093/infdis/jiaa637

Abstract

Developers of SARS-CoV-2 vaccines should consider some of the lessons from a 'new' vaccine introduced in 1921, namely BCG.

Keywords: BCG; COVID-19; SARS-CoV-2; vaccine.

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.